E Farinas1, P Honig. Show Affiliations » 1. Division of Pharmacovigilance, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, MD 20857, USA.
Abstract
Entities: Chemical Disease
Mesh： See more » Administration, OralAdultAgedDelayed-Action PreparationsEsophageal Stenosis/complicationsFemaleGastrointestinal Diseases/chemically inducedGastrointestinal Diseases/diagnosisHistamine H1 Antagonists/administration & dosageHistamine H1 Antagonists/adverse effectsHumansIntestinal Obstruction/chemically inducedIntestinal Obstruction/diagnosisLoratadine/administration & dosageLoratadine/adverse effects
Substances： See more » Delayed-Action PreparationsHistamine H1 AntagonistsLoratadine
Year: 1997 PMID： 9314359 DOI： 10.1016/s0091-6749(97)70260-4
Source DB: PubMed Journal: J Allergy Clin Immunol ISSN： 0091-6749 Impact factor: 10.793